ArticleScience translational medicine2017
Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
16.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 98 citations in OpenAlex.
- Signatures of the neutralizing dengue virus-reactive memory B cell repertoire identified by multiplexed envelope dimer probes.medRxiv : the preprint server for health sciences · 2026Article
- Targeting the Zika virus envelope domains I and III as a recombinant vaccine protects mice from lethal challenge.NPJ vaccines · 2026Article
- Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk.Nature communications · 2025Article
- Generation of a Human-Mouse Chimeric Anti-Japanese Encephalitis Virus and Zika Virus Monoclonal Antibody Using CDR Grafting.Microorganisms · 2025Article
- Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.The Lancet. Infectious diseases · 2025Review
- Evolution of Zika virus inVirus evolution · 2025Article
- Article
- Zika Virus-A Reemerging Neurotropic Arbovirus Associated with Adverse Pregnancy Outcomes and Neuropathogenesis.Pathogens (Basel, Switzerland) · 2024Review
- A human monoclonal antibody isolated from Japanese encephalitis virus vaccine-vaccinated volunteer neutralizing various flaviviruses.Frontiers in microbiology · 2024Article
- Review
- Article
- Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections.Biomedicines · 2022Review
- Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies.Cell host & microbe · 2022Article
- Host Molecules Regulating Neural Invasion of Zika Virus and Drug Repurposing Strategy.Frontiers in microbiology · 2022Review
- Prior Heterologous Flavivirus Exposure Results in Reduced Pathogenesis in a Mouse Model of Zika Virus Infection.Journal of virology · 2021Article
- Nanotechnology for virus treatment.Nano today · 2021Review
- Functionalized Nanoparticles in Prevention and Targeted Therapy of Viral Diseases With Neurotropism Properties, Special Insight on COVID-19.Frontiers in microbiology · 2021Review
- Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies.Journal of immunological methods · 2021Article
- Recovery of Synthetic Zika Virus Based on Rio-U1 Isolate Using a Genetically Stable Two Plasmid System and cDNA Amplification.Frontiers in microbiology · 2021Article
- Mapping the diverse structural landscape of the flavivirus antibody repertoire.Current opinion in virology · 2020Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 6 institutions in 2 countries.
Diogo M MagnaniDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.ORCID http://orcid.org/0000-0002-1773-2406
Thomas F RogersDepartment of Immunology and Microbiology and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID http://orcid.org/0000-0001-9756-327X
Nathan BeutlerDepartment of Immunology and Microbiology and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID http://orcid.org/0000-0003-3240-9524
Michael J RicciardiDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.ORCID http://orcid.org/0000-0002-8098-8666
Varian K BaileyDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.
Lucas Gonzalez-NietoDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.
Bryan BrineyDepartment of Immunology and Microbiology and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID http://orcid.org/0000-0001-9535-2866
Devin SokDepartment of Immunology and Microbiology and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID http://orcid.org/0000-0002-9354-1740
Khoa LeDepartment of Immunology and Microbiology and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID http://orcid.org/0000-0002-6770-3945
Alexander StrubelDepartment of Immunology and Microbiology and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID http://orcid.org/0000-0002-8175-962X
Martin J GutmanDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.
Núria Pedreño-LopezDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.ORCID http://orcid.org/0000-0001-6927-2301
Nathan D GrubaughDepartment of Immunology and Microbiology and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Cassia G T SilveiraDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-0932-7769
Helen S MaxwellDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.
Aline DominguesDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.
Mauricio A MartinsDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.ORCID http://orcid.org/0000-0001-8336-216X
David E LeeYerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Erica E OkwuaziYerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID http://orcid.org/0000-0003-2416-6585
Sherrie JeanYerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Elizabeth A StrobertYerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Ann ChahroudiYerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID http://orcid.org/0000-0001-7479-9546
Guido SilvestriYerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID http://orcid.org/0000-0001-6602-2470
Thomas H VanderfordYerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Esper G KallasDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.
Ronald C DesrosiersDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA.
Myrna C BonaldoLaboratório de Biologia Molecular de Flavivírus, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, Brazil.ORCID http://orcid.org/0000-0001-9899-3386
Stephen S WhiteheadLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Dennis R BurtonDepartment of Immunology and Microbiology and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA. burton@scripps.edu dwatkins@med.miami.edu.ORCID http://orcid.org/0000-0001-6711-9864
David I WatkinsDepartment of Pathology, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA. burton@scripps.edu dwatkins@med.miami.edu.ORCID http://orcid.org/0000-0001-6582-3305
University of Miami · USInternational AIDS Vaccine Initiative · USEmory University · USUniversidade Federal de São Paulo · BRFundação Oswaldo Cruz · BRNational Institutes of Health · US
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MUniversity of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ALLAN E RODRIGUEZ · 2007 to 2026
$33.8MLaboratory And Preclinical Studies Of FlavivirusesZIAAI000891 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WHITEHEAD, STEPHEN · 2009 to 2025
$17.5MYellow Fever Vector Development P01AI094420 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BONALDO, MYRNA C · 2012 to 2016
$11.4MPATHOGENESIS AND IMMUNOLOGY OF DISEASET32AI007244 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 1985 to 2022
$8.8MIpilimumab as an adjuvant for HIV vaccinesK01OD023032 · OD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARTINS, MAURICIO DE AGUIAR · 2016 to 2018
$993kNIAID NIH HHS P01 AI094420NIAID NIH HHS P30 AI073961NIAID NIH HHS T32 AI007244NIH HHS K01 OD023032NIH HHS P51 OD011132
Abstract
Therapies to prevent maternal Zika virus (ZIKV) infection and its subsequent fetal developmental complications are urgently required. We isolated three potent ZIKV-neutralizing monoclonal antibodies (nmAbs) from the plasmablasts of a ZIKV-infected patient-SMZAb1, SMZAb2, and SMZAb5-directed against two different domains of the virus. We engineered these nmAbs with Fc LALA mutations that abrogate Fcγ receptor binding, thus eliminating potential therapy-mediated antibody-dependent enhancement. We administered a cocktail of these three nmAbs to nonhuman primates 1 day before challenge with ZIKV and demonstrated that the nmAbs completely prevented viremia in serum after challenge. Given that numerous antibodies have exceptional safety profiles in humans, the cocktail described here could be rapidly developed to protect uninfected pregnant women and their fetuses.
Indexed as
AnimalsAntibodies, MonoclonalAntibodies, NeutralizingHumansImmunity, HumoralMacacaViral LoadZika Virus InfectionAntibodies, MonoclonalAntibodies, Neutralizing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.